5FBO

BTK-inhibitor co-structure

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.894 Å
  • R-Value Free: 0.236 
  • R-Value Work: 0.211 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history. 

Literature

Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.

Liu, J., Guiadeen, D., Krikorian, A., Gao, X., Wang, J., Boga, S.B., Alhassan, A.B., Yu, Y., Vaccaro, H., Liu, S., Yang, C., Wu, H., Cooper, A., de Man, J., Kaptein, A., Maloney, K., Hornak, V., Gao, Y.D., Fischmann, T.O., Raaijmakers, H., Vu-Pham, D., Presland, J., Mansueto, M., Xu, Z., Leccese, E., Zhang-Hoover, J., Knemeyer, I., Garlisi, C.G., Bays, N., Stivers, P., Brandish, P.E., Hicks, A., Kim, R., Kozlowski, J.A.

(2016) ACS Med Chem Lett 7: 198-203

  • DOI: 10.1021/acsmedchemlett.5b00463
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    • Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases. We report ...

    Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases. We report a series of compounds based on 8-amino-imidazo[1,5-a]pyrazine that are potent reversible BTK inhibitors with excellent kinase selectivity. Selectivity is achieved through specific interactions of the ligand with the kinase hinge and driven by aminopyridine hydrogen bondings with Ser538 and Asp539, and by hydrophobic interaction of trifluoropyridine in the back pocket. These interactions are evident in the X-ray crystal structure of the lead compounds 1 and 3 in the complex with the BTK enzyme. Our lead compounds show desirable PK profiles and efficacy in the preclinical rat collagen induced arthritis model.

    Organizational Affiliation: 

    WuXi PharmaTech Co. Ltd , 288 FuTe Zhong Road, No. 1 Building, WaiGaoQiao Free Trade Zone, Shanghai 200131, P. R. China.,Department of Early Development and Discovery Sciences, Merck Research Laboratories , 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tyrosine-protein kinase BTK
A
271Homo sapiensMutation(s): 0 
Gene Names: BTK (AGMX1, ATK, BPK)
EC: 2.7.10.2
Find proteins for Q06187 (Homo sapiens)
Go to Gene View: BTK
Go to UniProtKB:  Q06187
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
5WE
Query on 5WE
Download SDF File 
Download CCD File 
A
4-[8-azanyl-3-[(2~{S})-1-[4-(dimethylamino)butanoyl]pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-~{N}-(1,3-thiazol-2-yl)benzamide
C26 H30 N8 O2 S
HUXVNVAKNWKLJM-IBGZPJMESA-N
 Ligand Interaction
5WH
Query on 5WH
Download SDF File 
Download CCD File 
A
4-[8-azanyl-3-[(3~{R},6~{S})-1-cyclopropylcarbonyl-6-methyl-piperidin-3-yl]imidazo[1,5-a]pyrazin-1-yl]-3-fluoranyl-~{N}-[4-(trifluoromethyl)pyridin-2-yl]benzamide
C29 H27 F4 N7 O2
JUSWPUDQOKINJO-MAUKXSAKSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
5WHIC50: 0.3 - <10 nM (100) BINDINGDB
5WHIC50: 0.31 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.894 Å
  • R-Value Free: 0.236 
  • R-Value Work: 0.211 
  • Space Group: P 21 21 2
Unit Cell:
Length (Å)Angle (°)
a = 72.390α = 90.00
b = 104.470β = 90.00
c = 38.080γ = 90.00
Software Package:
Software NamePurpose
AutoPROCdata scaling
SCALAdata scaling
XDSdata reduction
BUSTERrefinement
BUSTERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2015-12-14 
  • Released Date: 2016-03-23 
  • Deposition Author(s): Fischmann, T.O.

Revision History 

  • Version 1.0: 2016-03-23
    Type: Initial release
  • Version 1.1: 2017-11-22
    Type: Derived calculations, Refinement description
  • Version 1.2: 2018-04-18
    Type: Data collection, Database references